Manufacturing methods for new drugs could be made greener and more efficient with the help of marine microbes.
Manufacturing methods for new drugs could be made greener and more efficient with the help of marine microbes. The project, which is being conducted by researchers at Heriot Watt University and Plymouth Marine Laboratory in collaboration with Ingenza Ltd (all UK) will use biochemical techniques to identify potentially useful enzymes in marine microbes.
"We are looking to find naturally occurring microbes that already have a built-in capacity to do the chemical reactions we want to perform in industry," Robert Speight, Operations Director at Ingenza Ltd (UK), explained in a statement. "There is every possibility of developing more efficient and sustainable manufacturing solutions for pharmaceuticals and agrochemicals in particular as a result of this search."
The team will be specifically looking for enzymes that can convert compounds which would previously have been waste products in the manufacturing process into the desired product. After finding these enzymes, the researchers will attempt to produce them in higher yield by treating the microbes under specific conditions. "The enzymes then undergo systematic testing to evaluate their activity, which enables us to pinpoint candidates that exhibit the best performance," Mark Keane, Director of Postgraduate Research, School of Engineering and Physical Sciences at Heriot-Watt University said in the statement.
The work was funded by the UK's Biotechnology and Biological Sciences Research Council (BBSRC) and the Technology Strategy Board. In the statement, Doug Kell, Chief Executive Professor of the BBSRC, said: "Green and White biotechnologies are going to be an increasingly important part of the manufacturing landscape. Looking to biological systems that have been finely tuned by evolution to solve problems, rather than starting from scratch every time, might seem an obvious thing to do. It does, however, require the bringing together of particular niche expertise."
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.